相关实验视频

Updated: Sep 12, 2025

Assay to Measure Nucleocytoplasmic Transport in Real Time within Motor Neuron-like NSC-34 Cells

Assay to Measure Nucleocytoplasmic Transport in Real Time within Motor Neuron-like NSC-34 Cells

Published on: May 16, 2017

挑战边界:c9orf72突变呈现为阿尔茨海默病

Federico Garrou¹, Fabiola De Marchi², Lucia Corrado³

¹Nuclear Medicine Unit, Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy.

Amyotrophic lateral sclerosis & frontotemporal degeneration

|August 6, 2025

概括

一个C9orf72基因扩张,通常会导致ALS和FTD,在患者身上呈现异常与阿尔茨海默氏症类似的症状. 这一案例突显了C9orf72疾病的多样性表现和与粉样蛋白病理学的潜在联系.

科学领域:

神经科学是一个神经科学.
遗传学是一个遗传学.
神经学神经学

背景情况:

C9orf72 六核酸重复扩张是肌缩侧面硬化症 (ALS) 和前性痴呆症 (FTD) 的主要遗传原因.
在C9orf72扩张和阿尔茨海默病 (AD) 病理学之间的关联仍然不完全理解.
与C9orf72相关的疾病中的表型变异需要进一步研究.

研究的目的:

报告C9orf72扩张的独特病例,其临床和成像特征表明阿尔茨海默病.
探索C9orf72基因突变和神经退行性疾病中的粉样蛋白病理之间的潜在相互作用.
为了强调与C9orf72扩展相关的表型异质性.

主要方法:

一个53岁的男性患有渐进性的认知和情绪缺陷的病例报告.
对粉样蛋白和生物标志物的脑脊液分析.
阳位子发射断层扫描 (PET) 成像,包括粉胺-PET和[18F]FDG-PET.
对C9orf72六核酸重复扩张的遗传检测.

主要成果:

患者表现出逐渐增长的记忆和语言缺陷,情绪障碍以及ALS-FTD家族病史.
脑脊液分析显示了粉样蛋白的阳性,由粉样蛋白-PET证实.
[18F]FDG-PET证明了AD的特征,与正常的陶氏度一起表现出时间平行体低代谢.
基因检测发现了一种致病性C9orf72扩张,也在患者的母亲身上发现.

结论:

这一案例说明了C9orf72相关疾病的显著表型异质性.
这些发现表明C9orf72扩张和潜在的粉样蛋白病理之间的潜在共发生或相互作用.
需要进一步的研究来阐明C9orf72突变与包括AD在内的多种神经退行性表型之间的复杂关系.

关键词:

这就是ALS.阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.C9orf7272 是一个很好的方法.在CSF的生物标志物中.FDGPETET 的时间.这是一个FTD.这种药物是甲胺醇 (Flutemetamol).粉胺PET是一种PET.行为症状行为症状认知障碍是一种认知障碍.早期发病的阿尔茨海默氏病.基因检测基因检测是指基因检测.神经退行症的神经退行症神经成像是一种神经成像.精准医学是一门精准医学.

更多相关视频

Measuring RAN Peptide Toxicity in C. elegans

Measuring RAN Peptide Toxicity in C. elegans

Published on: April 30, 2020

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...